Insulet Recalls Omnipod 5 Insulin Pumps After 18 Serious Adverse Events Due to Internal Tubing Defect
核心洞察
Insulet Corporation has issued a voluntary recall of specific lots of Omnipod 5 (搜索) insulin patch pumps due to small tears in internal tubing that can cause insulin leakage inside the device rather than delivery to the body.
The company has reported 18 serious adverse events associated with high blood glucose (搜索) levels, including hospitalizations and diabetic ketoacidosis (搜索), though no deaths have been reported.
The recall affects approximately 1.5% of Insulet's annual global Omnipod 5 (搜索) production, with the company expecting to incur up to $40 million in associated costs this year.
Insulet Corporation has issued a voluntary recall of certain lots of its Omnipod 5 (搜索) insulin patch pumps after identifying a manufacturing defect that could lead to dangerous under-delivery of insulin. The tubeless automated insulin delivery devices may contain small tears in their internal tubing, causing insulin to leak inside the pod instead of being delivered into the patient's body.
The recall announcement comes after Insulet reported 18 serious adverse events associated with high blood glucose (搜索) levels, including hospitalizations and cases of diabetic ketoacidosis (搜索) (DKA). No deaths have been reported in connection with the defective devices.
Manufacturing Defect and Clinical Impact
The identified problem involves small tears in the internal tubing that delivers insulin within the Omnipod 5 (搜索) devices. When this defect occurs, insulin may leak inside the pod rather than being properly infused into the patient's body, potentially leading to prolonged periods of high blood glucose (搜索) levels.
"If insulin is not delivered properly, users may experience high blood glucose (搜索) levels due to under-delivery of insulin," Insulet stated in its recall announcement. "In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (搜索) (DKA), a serious medical condition that requires prompt medical treatment."
The company has advised patients that affected devices may trigger a hazard alarm to notify users to remove their pod, emphasizing the importance of immediately changing to a new pod to resume full insulin delivery.
Recall Scope and Financial Impact
While Insulet has not disclosed the total number of affected devices, the company estimates the recall represents approximately 1.5% of its annual global Omnipod 5 (搜索) production. The financial impact is expected to be significant, with Insulet projecting up to $40 million in costs associated with the recall for this year.
Despite the recall costs, Insulet maintains its revenue growth expectations of 20% to 22% for 2026 on a constant currency basis. The company has stated that it does not expect the recall to disrupt customer shipments, product availability, or new patient starts for its Omnipod 5 (搜索) devices.
Company Response and Quality Improvements
Following an investigation into the manufacturing defect, Insulet has implemented updates to its manufacturing processes and quality controls. The company is providing free replacement pods to all affected customers and has established a system for patients to verify whether their pod lot numbers are included in the recall.
Patients are advised to check lot numbers on their pod tray lid, pod box, or the pod itself, as there may be multiple pods from impacted lots within the same box. The company warns that the risk of under-delivery increases if patients use more than one affected pod consecutively.
Industry Context
The recall adds to a series of recent safety events across the diabetes (搜索) technology industry. Other companies have faced regulatory scrutiny, including warning letters to insulin infusion set supplier Unomedical (搜索) over leaking infusion sets, glucose sensor maker Abbott (搜索) over accuracy concerns, and insulin pump maker Beta Bionics following reports of hyperglycemia (搜索) and hypoglycemia (搜索).
Mike Kratky, an analyst with Leerink Partners (搜索), characterized the news as "an unwelcome development" for Insulet but does not expect a significant shift in market share or commercial patterns as a result of the recall.